FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166624818> ?p ?o ?g. }

• W2166624818 endingPage "368" @default.
• W2166624818 startingPage "363" @default.
• W2166624818 abstract "In this largest phase II trial with advanced thymic carcinoma (TC), carboplatin and paclitaxel (CbP) showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of TC. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC.BackgroundThymic carcinoma (TC) is an exceptionally rare tumor, which has a very poor prognosis differing from thymoma. Till date, there has been no report of any results of clinical trials focusing on TC. The role of non-anthracycline-based chemotherapy has not been elucidated since the previous studies included a relatively small number of TC patients. This single-arm study evaluated carboplatin and paclitaxel (CbP) in chemotherapy-naive patients with advanced TC.Patients and methodsThe study treatment consisted of carboplatin (area under the curve 6) and paclitaxel (200 mg/m2) every 3 weeks for a maximum of six cycles. The primary end point was objective response rate (ORR) by independent review. The secondary end points included overall survival (OS), progression-free survival (PFS), and safety. Based on the SWOG 2-stage design, the planned sample size of 40 patients was determined to reject the ORR of 20% under the expectation of 40% with a power of 0.85 and a type I error of 0.05.ResultsForty patients from 21 centers were enrolled for this study from May 2008 to November 2010. Of the 39 patients evaluable for analysis, 36 were pathologically diagnosed by independent review, and 97% patients were eventually TC. There was 1/13 complete/partial responses with an ORR of 36% (95% confidence interval 21%–53%; P = 0.031). The median PFS was 7.5 (6.2–12.3) months, while OS did not reach the median value. Major adverse event was grade 3–4 neutropenia in 34 patients (87%). There was no treatment-related death.ConclusionsIn this largest trial with TC, CbP showed promising efficacy in advanced TC when compared with anthracycline-based chemotherapy, which is the current standard treatment of thymic neoplasm. Our results established that CbP, one of the standard treatments for non-small-cell lung cancer, might be an option as a chemotherapy regimen for TC." @default.
• W2166624818 created "2016-06-24" @default.
• W2166624818 creator A5002620609 @default.
• W2166624818 creator A5003016795 @default.
• W2166624818 creator A5003648443 @default.
• W2166624818 creator A5007279449 @default.
• W2166624818 creator A5012542775 @default.
• W2166624818 creator A5017095102 @default.
• W2166624818 creator A5021568645 @default.
• W2166624818 creator A5021868399 @default.
• W2166624818 creator A5024261346 @default.
• W2166624818 creator A5041976076 @default.
• W2166624818 creator A5044963688 @default.
• W2166624818 creator A5048745260 @default.
• W2166624818 creator A5061491770 @default.
• W2166624818 creator A5063898828 @default.
• W2166624818 creator A5065809272 @default.
• W2166624818 creator A5067259938 @default.
• W2166624818 creator A5087401551 @default.
• W2166624818 date "2015-02-01" @default.
• W2166624818 modified "2023-10-15" @default.
• W2166624818 title "A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L" @default.
• W2166624818 cites W1975225467 @default.
• W2166624818 cites W1988377668 @default.
• W2166624818 cites W1995247871 @default.
• W2166624818 cites W2012510274 @default.
• W2166624818 cites W2029883618 @default.
• W2166624818 cites W2037139573 @default.
• W2166624818 cites W2042515268 @default.
• W2166624818 cites W2052759126 @default.
• W2166624818 cites W2053244130 @default.
• W2166624818 cites W2053295326 @default.
• W2166624818 cites W2083719902 @default.
• W2166624818 cites W2090914388 @default.
• W2166624818 cites W2091075708 @default.
• W2166624818 cites W2103642803 @default.
• W2166624818 cites W2110654155 @default.
• W2166624818 cites W2125257681 @default.
• W2166624818 cites W2128501533 @default.
• W2166624818 cites W2139863684 @default.
• W2166624818 cites W2151090489 @default.
• W2166624818 cites W2151632124 @default.
• W2166624818 cites W2168071502 @default.
• W2166624818 doi "https://doi.org/10.1093/annonc/mdu541" @default.
• W2166624818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25403584" @default.
• W2166624818 hasPublicationYear "2015" @default.
• W2166624818 type Work @default.
• W2166624818 sameAs 2166624818 @default.
• W2166624818 citedByCount "81" @default.
• W2166624818 countsByYear W21666248182014 @default.
• W2166624818 countsByYear W21666248182015 @default.
• W2166624818 countsByYear W21666248182016 @default.
• W2166624818 countsByYear W21666248182017 @default.
• W2166624818 countsByYear W21666248182018 @default.
• W2166624818 countsByYear W21666248182019 @default.
• W2166624818 countsByYear W21666248182020 @default.
• W2166624818 countsByYear W21666248182021 @default.
• W2166624818 countsByYear W21666248182022 @default.
• W2166624818 countsByYear W21666248182023 @default.
• W2166624818 crossrefType "journal-article" @default.
• W2166624818 hasAuthorship W2166624818A5002620609 @default.
• W2166624818 hasAuthorship W2166624818A5003016795 @default.
• W2166624818 hasAuthorship W2166624818A5003648443 @default.
• W2166624818 hasAuthorship W2166624818A5007279449 @default.
• W2166624818 hasAuthorship W2166624818A5012542775 @default.
• W2166624818 hasAuthorship W2166624818A5017095102 @default.
• W2166624818 hasAuthorship W2166624818A5021568645 @default.
• W2166624818 hasAuthorship W2166624818A5021868399 @default.
• W2166624818 hasAuthorship W2166624818A5024261346 @default.
• W2166624818 hasAuthorship W2166624818A5041976076 @default.
• W2166624818 hasAuthorship W2166624818A5044963688 @default.
• W2166624818 hasAuthorship W2166624818A5048745260 @default.
• W2166624818 hasAuthorship W2166624818A5061491770 @default.
• W2166624818 hasAuthorship W2166624818A5063898828 @default.
• W2166624818 hasAuthorship W2166624818A5065809272 @default.
• W2166624818 hasAuthorship W2166624818A5067259938 @default.
• W2166624818 hasAuthorship W2166624818A5087401551 @default.
• W2166624818 hasBestOaLocation W21666248181 @default.
• W2166624818 hasConcept C121608353 @default.
• W2166624818 hasConcept C126322002 @default.
• W2166624818 hasConcept C141071460 @default.
• W2166624818 hasConcept C143998085 @default.
• W2166624818 hasConcept C203092338 @default.
• W2166624818 hasConcept C2776349617 @default.
• W2166624818 hasConcept C2776694085 @default.
• W2166624818 hasConcept C2776802502 @default.
• W2166624818 hasConcept C2777292972 @default.
• W2166624818 hasConcept C2777546739 @default.
• W2166624818 hasConcept C2778239845 @default.
• W2166624818 hasConcept C2778336483 @default.
• W2166624818 hasConcept C2781413609 @default.
• W2166624818 hasConcept C2781451048 @default.
• W2166624818 hasConcept C31760486 @default.
• W2166624818 hasConcept C530470458 @default.
• W2166624818 hasConcept C535046627 @default.
• W2166624818 hasConcept C71924100 @default.
• W2166624818 hasConceptScore W2166624818C121608353 @default.
• W2166624818 hasConceptScore W2166624818C126322002 @default.

• next